67
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

, , , , , & show all
Pages 245-250 | Published online: 28 Aug 2015

Figures & data

Table 1 Patient characteristics (n=16)

Table 2 All adverse events of FEC (N=16)

Table 3 All adverse events of docetaxel alone (N=8) and docetaxel plus trastuzumab (N=8)